Employees: 03 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 1987-05-05 (38 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LES ABRETS-EN-DAUPHINE (38490), Isere
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE IOBBI-NIVOL : revenue, balance sheet and financial ratios
PHARMACIE IOBBI-NIVOL is a French company
founded 38 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LES ABRETS-EN-DAUPHINE (38490),
this company of category PME
shows in 2023 a revenue of 2.0 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE IOBBI-NIVOL (SIREN 341490233)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
Revenue
N/C
N/C
1 968 289 €
N/C
N/C
N/C
N/C
N/C
Net income
41 248 €
28 817 €
101 903 €
118 936 €
79 785 €
118 981 €
104 950 €
68 702 €
EBITDA
N/C
N/C
145 945 €
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
5.2%
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE IOBBI-NIVOL generates positive net income of 41 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 69 k€ -> 41 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
41 248 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 149%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 31%. The balance between equity and debt is satisfactory.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
148.67%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
31.107%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
-432.899
-570.596
-3654.005
1772.782
494.756
283.169
209.352
148.67
Financial autonomy
-24.474
-14.0
-2.356
4.471
13.809
21.927
26.755
31.107
Repayment capacity
None
None
None
None
None
7.733
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
5.107%
None%
None%
Sector positioning
Debt ratio
148.672025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Average
In 2025, the debt ratio of PHARMACIE IOBBI-NIVOL (148.67) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
31.11%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Average
In 2025, the financial autonomy of PHARMACIE IOBBI-NIVOL (31.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
7.73 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE IOBBI-NIVOL (7.73) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 112.30. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
137.449
79.006
188.762
187.85
187.769
193.763
147.464
112.299
Interest coverage
None
None
None
None
None
4.574
None
None
Sector positioning
Liquidity ratio
112.32025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Watch-30 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE IOBBI-NIVOL (112.30) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
4.57x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of PHARMACIE IOBBI-NIVOL (4.6x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE IOBBI-NIVOL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
136 265 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
24
0
0
Customer payment term (days)
0
0
0
0
0
6
0
0
Supplier payment term (days)
0
0
0
0
0
38
0
0
Positioning of PHARMACIE IOBBI-NIVOL in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE IOBBI-NIVOL is estimated at
655 229 €
(range 444 641€ - 1 028 145€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
444k€655k€1028k€
655 229 €Range: 444 641€ - 1 028 145€
NAF 5 année 2025
Valuation method used
Net Income Multiple
41 248 €
×
15.9x
=655 229 €
Range: 444 642€ - 1 028 145€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE IOBBI-NIVOL with other companies in the same sector:
Frequently asked questions about PHARMACIE IOBBI-NIVOL
What is the revenue of PHARMACIE IOBBI-NIVOL ?
The revenue of PHARMACIE IOBBI-NIVOL in 2023 is 2.0 M€.
Is PHARMACIE IOBBI-NIVOL profitable?
Yes, PHARMACIE IOBBI-NIVOL generated a net profit of 41 k€ in 2025.
Where is the headquarters of PHARMACIE IOBBI-NIVOL ?
The headquarters of PHARMACIE IOBBI-NIVOL is located in LES ABRETS-EN-DAUPHINE (38490), in the department Isere.
Where to find the tax return of PHARMACIE IOBBI-NIVOL ?
The tax return of PHARMACIE IOBBI-NIVOL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE IOBBI-NIVOL operate?
PHARMACIE IOBBI-NIVOL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart